| Product Code: ETC6960214 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Denmark Gastrointestinal Diseases Drug Development Market Overview |
3.1 Denmark Country Macro Economic Indicators |
3.2 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, 2021 & 2031F |
3.3 Denmark Gastrointestinal Diseases Drug Development Market - Industry Life Cycle |
3.4 Denmark Gastrointestinal Diseases Drug Development Market - Porter's Five Forces |
3.5 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Molecular Targets, 2021 & 2031F |
3.7 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Marketed Drugs, 2021 & 2031F |
3.8 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Clinical Trials, 2021 & 2031F |
3.9 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 Denmark Gastrointestinal Diseases Drug Development Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of gastrointestinal diseases in Denmark |
4.2.2 Growing awareness about the importance of early diagnosis and treatment |
4.2.3 Advancements in technology and research leading to innovation in drug development for gastrointestinal diseases |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in Denmark |
4.3.2 High cost associated with drug development and clinical trials |
4.3.3 Limited availability of skilled professionals in the field of gastrointestinal diseases drug development |
5 Denmark Gastrointestinal Diseases Drug Development Market Trends |
6 Denmark Gastrointestinal Diseases Drug Development Market, By Types |
6.1 Denmark Gastrointestinal Diseases Drug Development Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Gastroenteritis, 2021- 2031F |
6.1.4 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Inflammatory Bowel Disease (IBD), 2021- 2031F |
6.1.5 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Irritable Bowel Syndrome, 2021- 2031F |
6.1.6 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Denmark Gastrointestinal Diseases Drug Development Market, By Molecular Targets |
6.2.1 Overview and Analysis |
6.2.2 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sodium Transporter NHE3 Inhibitor, 2021- 2031F |
6.2.3 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sphinogosine-1-Phosphate Receptor Functional Antagonist, 2021- 2031F |
6.2.4 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Tumor Necrosis Factor (TNF) Blocker, 2021- 2031F |
6.2.5 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Denmark Gastrointestinal Diseases Drug Development Market, By Marketed Drugs |
6.3.1 Overview and Analysis |
6.3.2 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Infliximab, 2021- 2031F |
6.3.3 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Adalimumab, 2021- 2031F |
6.3.4 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Mesalazine, 2021- 2031F |
6.3.5 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Denmark Gastrointestinal Diseases Drug Development Market, By Clinical Trials |
6.4.1 Overview and Analysis |
6.4.2 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Etrolizumab, 2021- 2031F |
6.4.3 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By SHP647, 2021- 2031F |
6.4.4 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ABX464, 2021- 2031F |
6.4.5 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ASP3291, 2021- 2031F |
6.4.6 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Denmark Gastrointestinal Diseases Drug Development Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Oral, 2021- 2031F |
6.5.3 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Injectable, 2021- 2031F |
6.6 Denmark Gastrointestinal Diseases Drug Development Market, By End-Users |
6.6.1 Overview and Analysis |
6.6.2 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Homecare, 2021- 2031F |
6.6.4 Denmark Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
7 Denmark Gastrointestinal Diseases Drug Development Market Import-Export Trade Statistics |
7.1 Denmark Gastrointestinal Diseases Drug Development Market Export to Major Countries |
7.2 Denmark Gastrointestinal Diseases Drug Development Market Imports from Major Countries |
8 Denmark Gastrointestinal Diseases Drug Development Market Key Performance Indicators |
8.1 Number of clinical trials initiated for gastrointestinal diseases drugs in Denmark |
8.2 Investment in RD for gastrointestinal diseases drug development in Denmark |
8.3 Number of new drug approvals for gastrointestinal diseases in Denmark |
9 Denmark Gastrointestinal Diseases Drug Development Market - Opportunity Assessment |
9.1 Denmark Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 Denmark Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Molecular Targets, 2021 & 2031F |
9.3 Denmark Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Marketed Drugs, 2021 & 2031F |
9.4 Denmark Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Clinical Trials, 2021 & 2031F |
9.5 Denmark Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 Denmark Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 Denmark Gastrointestinal Diseases Drug Development Market - Competitive Landscape |
10.1 Denmark Gastrointestinal Diseases Drug Development Market Revenue Share, By Companies, 2024 |
10.2 Denmark Gastrointestinal Diseases Drug Development Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here